Charles River Laboratories International, Inc. (NYSE:CRL) Position Reduced by Whittier Trust Co.

Whittier Trust Co. reduced its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 35.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 264 shares of the medical research company’s stock after selling 144 shares during the period. Whittier Trust Co.’s holdings in Charles River Laboratories International were worth $49,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Versant Capital Management Inc grew its position in Charles River Laboratories International by 1,071.4% during the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after purchasing an additional 150 shares in the last quarter. Pinnacle Bancorp Inc. grew its holdings in shares of Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after buying an additional 65 shares in the last quarter. Tortoise Investment Management LLC raised its position in Charles River Laboratories International by 77.7% during the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company’s stock valued at $49,000 after buying an additional 115 shares during the period. ORG Wealth Partners LLC purchased a new stake in Charles River Laboratories International in the 4th quarter worth about $56,000. Finally, Wilmington Savings Fund Society FSB purchased a new stake in shares of Charles River Laboratories International in the third quarter worth approximately $59,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Price Performance

Shares of Charles River Laboratories International stock opened at $167.29 on Tuesday. Charles River Laboratories International, Inc. has a 1-year low of $150.79 and a 1-year high of $273.57. The firm has a fifty day simple moving average of $165.66 and a 200-day simple moving average of $183.49. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $8.55 billion, a price-to-earnings ratio of 1,115.28, a PEG ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business’s revenue was down 1.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.46 EPS. On average, sell-side analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on CRL. Robert W. Baird lowered their price objective on shares of Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating on the stock in a research report on Thursday, February 20th. UBS Group reaffirmed a “neutral” rating and issued a $185.00 price target (down from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Barclays reduced their price objective on Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 18th. The Goldman Sachs Group lowered Charles River Laboratories International from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $190.00 to $170.00 in a research report on Friday. Finally, JPMorgan Chase & Co. reduced their price target on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a report on Thursday, February 20th. One analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $189.77.

Insider Activity at Charles River Laboratories International

In related news, COO Birgit Girshick acquired 1,514 shares of the company’s stock in a transaction dated Thursday, February 20th. The shares were bought at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the acquisition, the chief operating officer now owns 55,058 shares in the company, valued at $9,064,198.54. This trade represents a 2.83 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO James C. Foster bought 6,075 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, February 20th. The stock was bought at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the purchase, the chief executive officer now owns 183,639 shares of the company’s stock, valued at $30,302,271.39. This trade represents a 3.42 % increase in their position. The disclosure for this purchase can be found here. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).